Repulsive separation of the cytoplasmic ends of transmembrane helices 3 and 6 is linked to receptor activation in a novel thyrotropin receptor mutant (M626I)

Molecular Endocrinology

Volumn 20, Issue 4, 2006, Pages 893-903

  Ringkananont, Usanee ^a   Van Durme, Joost ^b   Montanelli, Lucia ^b   Ugrasbul, Figen ^c   Yu, Y Miles ^c   Weiss, Roy E ^a   Refetoff, Samuel ^a   Grasberger, Helmut ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; ISOLEUCINE; RHODOPSIN; SERPENTINE; THYROTROPIN RECEPTOR;

ANIMAL CELL; ARTICLE; CASE REPORT; CELL MEMBRANE; CELL SURFACE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOPLASM; FEMALE; GENE MUTATION; HUMAN; HYPERTHYROIDISM; MALE; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SEQUENCE HOMOLOGY; SITE DIRECTED MUTAGENESIS; STEREOSPECIFICITY;

AMINO ACID SUBSTITUTION; BASE SEQUENCE; DNA; FEMALE; GENES, DOMINANT; HETEROZYGOTE; HUMANS; HYPERTHYROIDISM; INFANT; KINETICS; MALE; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; PEDIGREE; POINT MUTATION; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, THYROTROPIN; RECOMBINANT PROTEINS; THERMODYNAMICS; TRANSFECTION;

ANIMALIA;

EID: 33645406071     PISSN: 08888809     EISSN: 08888809     Source Type: Journal    
DOI: 10.1210/me.2005-0339     Document Type: Article

References (45)

1. Bourne HR 1997 How receptors talk to trimeric G proteins. Curr Opin Cell Biol 9:134-142
2. Gether U, Kobilka BK 1998 G protein-coupled receptors. II. Mechanism of agonist activation. J Biol Chem 273:17979-17982
3. Wess J 1997 G-protein-coupled receptors: molecular mechanisms involved in receptor activation and selectivity of G-protein recognition. FASEB J 11:346-354
4. Gether U 2000 Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev 21:90-113
5. Lin SW, Sakmar TP 1996 Specific tryptophan UV-absorbance changes are probes of the transition of rhodopsin to its active state. Biochemistry 35:11149-11159
6. Sheikh SP, Vilardarga JP, Baranski TJ, Lichtarge O, Iiri T, Meng EC, Nissenson RA, Bourne HR 1999 Similar structures and shared switch mechanisms of the β2-adrenoceptor and the parathyroid hormone receptor. Zn(II) bridges between helices III and VI block activation. J Biol Chem 274:17033-17041
7. Farrens DL, Altenbach C, Yang K, Hubbell WL, Khorana HG 1996 Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science 274:768-770
8. Gether U, Lin S, Ghanouni P, Ballesteros JA, Weinstein H, Kobilka BK 1997 Agonists induce conformational changes in transmembrane domains III and VI of the β2 adrenoceptor. EMBO J 16:6737-6747
9. Kobilka BK, Gether U 1998 Examination of ligand-induced conformational changes in the β2-adrenergic receptor by fluorescence spectroscopy. Adv Pharmacol 42:470-473
10. Spalding TA, Burstein ES, Wells JW, Brann MR 1997 Constitutive activation of the m5 muscarinic receptor by a series of mutations at the extracellular end of transmembrane 6. Biochemistry 36:10109-10116
11. Burstein ES, Spalding TA, Brann MR 1998 The second intracellular loop of the m5 muscarinic receptor is the switch which enables G-protein coupling. J Biol Chem 273:24322-24327
12. Ballesteros JA, Jensen AD, Liapakis G, Rasmussen SG, Shi L, Gether U, Javitch JA 2001 Activation of the β2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J Biol Chem 276:29171-29177
13. Parrish W, Eilers M, Ying W, Konopka JB 2002 The cytoplasmic end of transmembrane domain 3 regulates the activity of the Saccharomyces cerevisiae G-protein-coupled α-factor receptor. Genetics 160:429-443
14. Sheikh SP, Zvyaga TA, Lichtarge O, Sakmar TP, Bourne HR 1996 Rhodopsin activation blocked by metal-ion-binding sites linking transmembrane helices C and F. Nature 383:347-350
15. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M 2000 Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289:739-745
16. Li J, Edwards PC, Burghammer M, Villa C, Schertler GF 2004 Structure of bovine rhodopsin in a trigonal crystal form. J Mol Biol 343:1409-1438
17. Shapiro DA, Kristiansen K, Weiner DM, Kroeze WK, Roth BL 2002 Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6. J Biol Chem 277:11441-11449
18. Okada T, Palczewski K 2001 Crystal structure of rhodopsin: implications for vision and beyond. Curr Opin Struct Biol 11:420-426
19. Ballesteros JA, Weinstein H 1995 Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci 25:366-428
20. Govaerts C, Lefort A, Costagliola S, Wodak SJ, Ballesteros JA, Van Sande J, Pardo L, Vassart G 2001 A conserved Asn in transmembrane helix 7 is an on/off switch in the activation of the thyrotropin receptor. J Biol Chem 276:22991-22999
21. Tonacchera M, Van Sande J, Cetani F, Swillens S, Schvartz C, Winiszewski P, Portmann L, Dumont JE, Vassart G, Parma J 1996 Functional characteristics of three new germline mutations of the thyrotropin receptor gene causing autosomal dominant toxic thyroid hyperplasia. J Clin Endocrinol Metab 81:547-554
22. Urizar E, Claeysen S, Deupi X, Govaerts C, Costagliola S, Vassart G, Pardo L 2005 An activation switch in the rhodopsin family of G protein-coupled receptors: the thyrotropin receptor. J Biol Chem 280:17135-17141
23. Finkelstein AV, Ptitsyn OB 2002 Protein physics: a course of lectures. London: Academic Press; 23-31
24. Baranski TJ, Herzmark P, Lichtarge O, Gerber BO, Trueheart J, Meng EC, Iiri T, Sheikh SP, Bourne HR 1999 C5a receptor activation. Genetic identification of critical residues in four transmembrane helices. J Biol Chem 274:15757-15765
25. Hjorth SA, Orskov C, Schwartz TW 1998 Constitutive activity of glucagon receptor mutants. Mol Endocrinol 12:78-86
26. Kosugi S, Mori T, Shenker A 1996 The role of Asp578 in maintaining the inactive conformation of the human lutropin/choriogonadotropin receptor. J Biol Chem 271:31813-31817
27. Burstein ES, Spalding TA, Brann MR 1996 Amino acid side chains that define muscarinic receptor/G-protein coupling. Studies of the third intracellular loop. J Biol Chem 271:2882-2885
28. Parent JL, Le Gouill C, de Brum-Fernandes AJ, Rola-Pleszczynski M, Stankova J 1996 Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor. J Biol Chem 271:7949-7955
29. Tao YX, Abell AN, Liu X, Nakamura K, Segaloff DL 2000 Constitutive activation of G protein-coupled receptors as a result of selective substitution of a conserved leucine residue in transmembrane helix III. Mol Endocrinol 14:1272-1282
30. Shinozaki H, Fanelli F, Liu X, Jaquette J, Nakamura K, Segaloff DL 2001 Pleiotropic effects of substitutions of a highly conserved leucine in transmembrane helix III of the human lutropin/choriogonadotropin receptor with respect to constitutive activation and hormone responsiveness. Mol Endocrinol 15:972-984
31. Zhang M, Mizrachi D, Fanelli F, Segaloff DL 2005 The formation of a salt bridge between helices 3 and 6 is responsible for the constitutive activity and lack of hormone responsiveness of the naturally occurring L457R mutation of the human lutropin receptor. J Biol Chem 280:26169-26176
32. Prioleau C, Visiers I, Ebersole BJ, Weinstein H, Sealfon SC 2002 Conserved helix 7 tyrosine acts as a multistate conformational switch in the 5HT2C receptor. Identification of a novel "locked-on" phenotype and double revertant mutations. J Biol Chem 277:36577-36584
33. Abell AN, Segaloff DL 1997 Evidence for the direct involvement of transmembrane region 6 of the lutropin/choriogonadotropin receptor in activating Gs. J Biol Chem 272:14586-14591
34. Kremer H, Mariman E, Otten BJ, Moll Jr GW, Stoelinga GB, Wit JM, Jansen M, Drop SL, Faas B, Ropers HH, Brunner HG 1993 Cosegregation of missense mutations of the luteinizing hormone receptor gene with familial male-limited precocious puberty. Hum Mol Genet 2:1779-1783
35. Kosugi S, Van Dop C, Geffner ME, Rabl W, Carel JC, Chaussain JL, Mori T, Merendino Jr JJ, Shenker A 1995 Characterization of heterogeneous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty. Hum Mol Genet 4:183-188
36. Abell AN, McCormick DJ, Segaloff DL 1998 Certain activating mutations within helix 6 of the human luteinizing hormone receptor may be explained by alterations that allow transmembrane regions to activate Gs. Mol Endocrinol 12:1857-1869
37. Lin Z, Shenker A, Pearlstein R 1997 A model of the lutropin/ choriogonadotropin receptor: insights into the structural and functional effects of constitutively activating mutations. Protein Eng 10:501-510
38. Fanelli F, Verhoef-Post M, Timmerman M, Zeilemaker A, Martens JW, Themmen AP 2004 Insight into mutationinduced activation of the luteinizing hormone receptor: molecular simulations predict the functional behavior of engineered mutants at M398. Mol Endocrinol 18:1499-1508
39. Karges B, Krause G, Homoki J, Debatin KM, de Roux N, Karges W 2005 TSH receptor mutation V509A causes familial hyperthyroidism by release of interhelical constraints between transmembrane helices TMH3 and TMH5. J Endocrinol 186:377-385
40. de Roux N, Misrahi M, Chatelain N, Gross B, Milgrom E 1996 Microsatellites and PCR primers for genetic studies and genomic sequencing of the human TSH receptor gene. Mol Cell Endocrinol 117:253-256
41. Libert F, Lefort A, Gerard C, Parmentier M, Perret J, Ludgate M, Dumont JE, Vassart G 1989 Cloning, sequencing and expression of the human thyrotropin (TSH) receptor: evidence for binding of autoantibodies. Biochem Biophys Res Commun 165:1250-1255
42. Costagliola S, Rodien P, Many MC, Ludgate M, Vassart G 1998 Genetic immunization against the human thyrotropin receptor causes thyroiditis and allows production of monoclonal antibodies recognizing the native receptor. J Immunol 160:1458-1465
43. Vlaeminck-Guillem V, Ho SC, Rodien P, Vassart G, Costagliola S 2002 Activation of the cAMP pathway by the TSH receptor involves switching of the ectodomain from a tethered inverse agonist to an agonist. Mol Endocrinol 16:736-746
44. Vriend G 1990 WHAT IF: a molecular modeling and drug design program. J Mol Graph 8:52-56:29
45. Krieger E, Darden T, Nabuurs SB, Finkelstein A, Vriend G 2004 Making optimal use of empirical energy functions: force-field parameterization in crystal space. Proteins 57:678-683